Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

May 24, 2022 by Alan Khadavi

Lirentelimab study for Chronic Urticaria (Hives)

Lirentelimab is an anti-sialic acid-binding immunoglobulin-like lectin 8 mAb that selectively inhibits mast cells and depletes eosinophils. It is being studied for chronic urticaria that is often refractory to standard therapy.

Stepwise approach to Chronic Urticaria (Chronic Hives)

Chronic urticaria is a mast cell disease that causes recurrent itching, hives and angioedema for more than 6 weeks. It can occur spontaneously or caused by sweat inducing exercise or by minor stroking, rubbing or scratching the skin, dermographism.

First line therapy is oral H1-antihistamines up to 4x day. However there remains many refractory cases. Xolair is the next step in therapy. However there still remains patients who do not respond to therapy. Severe Hives Treatment (Xolair and Cyclosporine)

Siglec-8 is an inhibitory receptor expressed on mast cells and eosinophils. Engagement of this receptor has been shown to inhibit mast cell activation.

Lirentelimab (AK002) is an investigational medicine, first in class, humanized monoclonal antibody against Siglec-8. Its been shown to suppress mast cell activity in inflammatory pathways and deplete eosinophils. Lirentelimab has been evaluated in trials with those who have eosinophilic GI disorders and conjunctivitis and systemic mastocytosis.

A recent phase 2 study enrolled patients with refractory chronic urticaria who failed 4 X day of H1 antihistamines. Patients received 6 monthly infusions of lirentelimab. Urticarial Control Test scores improved with lirentelimab across all dosages. In addition, lirentelimab treatment led to improved signs and symptoms by the Hives Severity Score and Itch Severity Score for patients who failed Xolair. Side effects were minimal and there were no drug related serious adverse events.

This was a small sample size and more studies are needed, but lirentelimab may be a promising treatment option for patients who fail other drug measures. By binding directly to mast cells and inhibiting them, lirentelimab is using a novel approach to decrease the release of histamine in chronic urticaria patients. This treatment may also possibly be used to treat other allergic diseases in the future as well.

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

July 5, 2022

Itepekimab (Anti IL-33) & Brodalumab (Anti IL-25) for Asthma

Itepekimab and Brodalumab

June 18, 2022

Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis

roflumilast tapinarof

June 9, 2022

Avocado Allergy Comes in Many Flavors

avocado allergy

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

April 19, 2022

Fasenra for Nasal Polyps, a new treatment option

fasenra for nasal polyps

April 19, 2022

Asivatrep a new topical treatment for Eczema

asivatrep cream

April 3, 2022

Kiwi Allergy can come in many flavors

Kiwi allergy

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page